BTIM (BTIM) Stock Price & Analysis
BTIM (BTIM) rose 0.00% to USD 0 as of June 10, 2026 at 05:28 UTC, according to Nexqual real-time market data.
BTIM last closed at USD 0; the session ranged USD 0–0 on volume of 100,000 shares. Market capitalization is $6,043, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 05:28 UTC.
Key Statistics (as of June 10, 2026 at 05:28 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 100,000 shares |
| Market Cap | $6,043 |
| Exchange | PNK |
Technical Analysis (BTIM)
Nexqual's technical model rates BTIM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 05:28 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (BTIM)
Wall Street analysts rate BTIM "None", per Nexqual as of June 10, 2026 at 05:28 UTC.
| Consensus Rating | None |
|---|
Earnings (BTIM)
Source: Nexqual, June 10, 2026 at 05:28 UTC.
Financials & Fundamentals (BTIM)
| Total Revenue | $183 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -1762842.60% |
| Profit Margin | +0.00% |
| Current Ratio | 0.07 |
| Total Cash | $186,843 |
| Total Debt | $2.56M |
| Free Cash Flow | $-871,131 |
Source: Nexqual, June 10, 2026 at 05:28 UTC.
Financial Health Score (BTIM)
Nexqual rates BTIM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:28 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $187K cash vs $3M debt |
| Cash Flow | Weak — FCF negative: -$871K, burning cash |
| Efficiency | Mixed — No data |
Ownership (BTIM)
| Insider Ownership | +54.22% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 60.44M |
| Float | 29.01M |
Source: Nexqual, June 10, 2026 at 05:28 UTC.
Leadership (BTIM)
BTIM is led by Joseph Johnson, CEO & Director, per Nexqual as of June 10, 2026 at 05:28 UTC.
| CEO & Director | Joseph Johnson |
|---|---|
| CFO & Director | Mario Antone Beckles (age 51) |
| Chief Marketing Officer | Patrick Burkert (age 40) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ISCO | International Stem Cell Corp. | USD 0.17 | ▼ 5.56% |
| CCEL | Cryo-Cell International, Inc. | USD 3.45 | ▼ 1.43% |
| MCET | MULTICELL TECHNOLOGIES INC | USD 0 | ▲ 0% |
| FDCT | FDCTech, Inc. | USD 0.06 | ▼ 1.64% |
| SCAL | Stem Cell Authority, Ltd. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:28 UTC. This page is informational and not investment advice.